Option Care Health, Inc. (NASDAQ:OPCH) Given Average Rating of “Moderate Buy” by Analysts

Option Care Health, Inc. (NASDAQ:OPCH) has received an average recommendation of “Moderate Buy” from the eleven ratings firms that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $37.2727.

OPCH has been the subject of several analyst reports. Bank of America raised their target price on Option Care Health from $32.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Citigroup reiterated an “outperform” rating on shares of Option Care Health in a research report on Tuesday, January 13th. Morgan Stanley increased their price target on shares of Option Care Health from $35.00 to $38.00 and gave the stock an “overweight” rating in a report on Tuesday, January 13th. Citizens Jmp restated a “market outperform” rating and issued a $38.00 price objective (up from $36.00) on shares of Option Care Health in a research report on Tuesday, January 13th. Finally, Wall Street Zen cut shares of Option Care Health from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. V Square Quantitative Management LLC purchased a new stake in shares of Option Care Health in the fourth quarter worth $25,000. Cornerstone Planning Group LLC grew its position in Option Care Health by 7,621.4% during the third quarter. Cornerstone Planning Group LLC now owns 1,081 shares of the company’s stock worth $30,000 after buying an additional 1,067 shares in the last quarter. McIlrath & Eck LLC purchased a new position in Option Care Health during the second quarter worth about $37,000. Elevation Point Wealth Partners LLC bought a new position in Option Care Health in the 2nd quarter worth about $40,000. Finally, Advisory Services Network LLC bought a new position in Option Care Health in the 3rd quarter worth about $35,000. 98.05% of the stock is currently owned by hedge funds and other institutional investors.

Option Care Health Trading Up 0.3%

NASDAQ:OPCH opened at $28.49 on Thursday. The company has a market cap of $4.46 billion, a P/E ratio of 22.26, a P/E/G ratio of 1.59 and a beta of 0.85. The stock’s fifty day moving average price is $32.94 and its two-hundred day moving average price is $30.74. Option Care Health has a 1 year low of $24.24 and a 1 year high of $36.80. The company has a debt-to-equity ratio of 0.87, a current ratio of 1.53 and a quick ratio of 0.96.

Option Care Health (NASDAQ:OPCH) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $0.46 earnings per share for the quarter, meeting the consensus estimate of $0.46. Option Care Health had a return on equity of 18.57% and a net margin of 3.67%.The company had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.46 billion. During the same period in the previous year, the business earned $0.44 earnings per share. The firm’s quarterly revenue was up 8.8% compared to the same quarter last year. As a group, analysts expect that Option Care Health will post 1.22 EPS for the current year.

About Option Care Health

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.